A multi-center, unblinded, case-crossover study randomly to determine whether blood transcriptomic changes, pre- and posttreatment of a prodrome with Ruconest (recombinant human C1-INH), overlapped with changes pre- and post-treatment of an acute attack
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Conestat alfa (Primary)
- Indications Hereditary angioedema
- Focus Pharmacodynamics
Most Recent Events
- 14 Apr 2023 New trial record
- 27 Feb 2023 Results presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology